Strong organic growth and margin expansion
- Net revenue increased by 12 per cent to EUR 91.0m (81.3) with organic growth of 11 per cent
- Adjusted EBITA increased 22 per cent to EUR 24.7m (20.3) corresponding to a margin of 27.2 per cent (25.0)
- Operating profit (EBIT) increased 30 per cent to EUR 13.2m (10.1)
- Profit of EUR 5.1m (3.2) and earnings per share before and after dilution EUR 0.01 (0.01)
- Cash flow from operating activities of EUR 5.9m (-58.5)
"We report double digit organic growth, grew adjusted EBITA with 22 per cent and improved our margins in the second quarter. Our three largest segments delivered strong performance, and we continued to execute on our strategic agenda, addressing unmet medical needs of companion animals across the globe by delivering innovation, driving cross-sales and operational improvements as well as expanding our educations", says Patrik Eriksson, CEO of Vimian Group and continues:
"I see significant runway for both organic and acquisition driven growth over the years to come. We are well-capitalised and focused on broadening the portfolio and strengthening our geographic reach."
A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.
To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://conference.financialhearings.com/teleconference/?id=50047233
To attend the webcast:
Link: https://ir.financialhearings.com/vimian-group-q2-report-2024
Related presentation materials will be available on Vimian's website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.
For further information, please contact:
Maria Dahllöf Tullberg
Head of IR, Communications & Sustainability
maria.tullberg@vimian.com
+46 736 26 88 86
About Vimian
Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market's most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 15,000 veterinary clinics and 1,700 labs, sells to over 80 markets, has 1,100 employees and annual revenues of approximately EUR 330 million. For more information, please visit: www.vimian.com. FNCA Sweden AB is appointed the Company's Certified Adviser.
This information is information that Vimian Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-15 07:45 CEST.
